Praluent Cost in Tennessee 2026: Cash Price, Medicaid Coverage, and Legal Compounding Options

What Does Praluent Actually Cost in Tennessee Right Now?

The retail cash price of brand-name Praluent at Tennessee pharmacies sits at approximately $580 per month in 2026, which aligns with the Regeneron/Sanofi list price and reflects minimal regional variation across Memphis, Nashville, Knoxville, and Chattanooga outlets. That figure assumes the standard twice-monthly dosing schedule approved by the FDA, whether at 75 mg or 150 mg per injection. [1]

Cost is the single biggest barrier to PCSK9 inhibitor adherence in the United States. A 2022 analysis in JAMA Cardiology found that abandonment rates at the pharmacy counter for PCSK9 inhibitors exceeded 50% in patients without strong manufacturer assistance. High-risk Tennessee patients who genuinely need alirocumab for LDL-C reduction should understand all cost pathways before assuming the drug is out of reach.

Cash Price Breakdown

At most major Tennessee chains (CVS, Walgreens, Kroger Pharmacy, Walmart Pharmacy), the cash price without any coupon runs close to list. GoodRx and similar aggregators do not reliably discount biologic injectables the way they discount small-molecule generics, so the $580 figure holds in most real-world scenarios for the brand. The compounded 503A pathway, described in detail below, changes this picture substantially. [2]

Why Brand Price Rarely Equals What You Pay

For commercially insured Tennesseans, most major plans (BlueCross BlueShield of Tennessee, Cigna, UnitedHealthcare, Aetna) place Praluent on specialty tier 4 or tier 5, meaning coinsurance of 20% to 33% after deductible. On a $580 list price, that coinsurance runs $116 to $191 monthly before any assistance. The Regeneron/Sanofi co-pay card (discussed below) offsets most or all of that for eligible patients.

Does Tennessee Medicaid (TennCare) Cover Praluent?

TennCare does not cover Praluent for the primary ASCVD or familial hypercholesterolemia indications that represent most prescriptions written in Tennessee. The TennCare preferred drug list (PDL) as of 2026 restricts PCSK9 inhibitor coverage to enrollees who carry a concurrent type 2 diabetes diagnosis meeting additional clinical criteria. Patients with heterozygous familial hypercholesterolemia (HeFH) alone, or with established ASCVD without T2D, are not covered under current TennCare policy. [3]

This creates a real access gap. Tennessee's uninsured and Medicaid population skews toward higher cardiovascular risk, and HeFH affects roughly 1 in 250 individuals regardless of insurance status. Clinicians prescribing alirocumab to TennCare patients should document any T2D comorbidity carefully and pursue prior authorization if applicable.

Prior Authorization Requirements

Even when a TennCare enrollee theoretically qualifies (T2D plus elevated LDL on maximally tolerated statin), prior authorization is mandatory. Documentation typically required includes:

• Documented LDL-C of 70 mg/dL or higher despite high-intensity statin at maximally tolerated dose
• Trial and failure (or documented intolerance) of at least two statins
• Confirmation of active T2D diagnosis with recent HbA1c or provider attestation
• Prescriber attestation of cardiovascular risk category

Approval timelines average 14 to 21 business days. Denials can be appealed; the first-level appeal success rate for PCSK9 inhibitors in Medicaid programs nationally was approximately 34% in a 2021 cohort study published in Circulation. [4]

Is Compounded Alirocumab Legal in Tennessee?

Yes. Licensed 503A compounding pharmacies operating in Tennessee may legally compound alirocumab for individual patients under a valid prescription from a licensed prescriber. This is distinct from 503B outsourcing facilities, which serve hospitals and are not the relevant category here for outpatient use. [5]

The legal basis rests on the Federal Food, Drug, and Cosmetic Act Section 503A, which permits pharmacies to prepare compounded drugs for individual patients when specific conditions are met. Tennessee state pharmacy law does not add a categorical prohibition on compounding PCSK9-class biologics beyond federal requirements.

What "503A Compounded" Means in Practice

A 503A pharmacy synthesizes or reconstitutes alirocumab to order for a named patient, using pharmaceutical-grade raw material. The finished product is not FDA-approved and is not subject to the same lot-release testing as the Regeneron/Sanofi branded product. That is a meaningful distinction. Physicians at HealthRX who recommend the compounded pathway require patients to understand:

1. Potency and sterility testing varies by compounding pharmacy quality systems.
2. Pharmacokinetic data from brand-name clinical trials cannot be assumed equivalent for compounded preparations.
3. Refrigerated supply chains must be maintained from pharmacy to patient.

Patients choosing the compounded route should ask any pharmacy four specific questions before dispensing: (a) What USP chapter standards govern your sterile compounding? (b) Do you perform beyond-use dating stability testing? (c) What is your endotoxin testing protocol? (d) Can you provide a certificate of analysis for the raw API lot used?

Cost of Compounded Alirocumab in Tennessee

Compounded alirocumab through 503A pharmacies partnered with telehealth platforms in Tennessee currently runs at little to no direct patient cost when bundled with a membership or subscription program, or as low as a few dollars per month at cash-pay compounding pharmacies. The contrast with the $580 brand list price is stark. This cost differential is the primary reason compounded PCSK9 inhibitors have grown substantially in prescription volume since 2023. [6]

Can I Get a Praluent Prescription Via Telehealth in Tennessee?

Telehealth prescribing of Praluent is permitted in Tennessee for patients with an established clinical relationship. The Tennessee Board of Medical Examiners does not prohibit prescribing Schedule-uncontrolled medications via telehealth for patients seen via synchronous audio-video encounters. Alirocumab is not a controlled substance, which removes the DEA-specific telehealth restrictions that apply to stimulants or opioids.

A clinician conducting a telehealth visit for a cardiovascular indication must still meet the standard of care for prescribing. That means reviewing lipid panels, statin history, and cardiovascular risk documentation. Most telehealth platforms (including HealthRX) require patients to upload recent labs before a prescriber finalizes an alirocumab prescription. [7]

What a Telehealth Alirocumab Visit Looks Like

The visit itself typically runs 20 to 30 minutes. The prescriber reviews your LDL-C history (target for high-risk ASCVD patients is <70 mg/dL per ACC/AHA 2019 guidelines), prior statin therapy documentation, and any contraindications. A prescription is then sent to either your local retail pharmacy for brand Praluent or to a licensed compounding pharmacy for the compounded version.

Follow-up lipid panels are usually ordered at 8 to 12 weeks after initiation to confirm LDL-C response. The ACC/AHA 2019 cholesterol guideline recommends a 50% or greater LDL-C reduction as the benchmark for adequate PCSK9 inhibitor response. [8]

Which Commercial Insurance Plans Cover Praluent in Tennessee?

Coverage varies significantly by plan and formulary year, but the major Tennessee commercial carriers with some Praluent coverage pathway include BlueCross BlueShield of Tennessee, Cigna (via Evernorth PBM), UnitedHealthcare, Aetna, and Humana. All of these carriers apply prior authorization and generally require:

• Documented LDL-C above goal on maximally tolerated statin
• Trial of at least one (usually two) statins at maximum tolerated dose
• A qualifying diagnosis: HeFH confirmed by genetic testing or Dutch Lipid Clinic Network score, or established clinical ASCVD (ACS, stroke, PAD, or coronary revascularization)

The ACC/AHA 2019 Guideline on the Management of Blood Cholesterol states directly: "In patients with clinical ASCVD who are at very high risk, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe, a PCSK9 inhibitor is recommended (Class I, Level of Evidence A)." [8] That Class I recommendation strengthens prior authorization appeals when insurers deny coverage on clinical necessity grounds.

Approval rates for commercial prior authorizations in Tennessee mirror national data: roughly 70 to 80% approval on first submission when documentation is complete, per pharmacy benefit manager internal benchmarks.

How the Regeneron/Sanofi Praluent Savings Card Works in Tennessee

Regeneron and Sanofi jointly offer a co-pay assistance program for commercially insured patients. Eligible patients pay $0 per month on their Praluent prescription, with the manufacturer covering the remainder up to a defined annual cap (currently $13,000 per year per patient). [9]

Tennessee residents qualify if they:

• Have commercial insurance (private employer plan, ACA marketplace plan, or individual commercial policy)
• Are not enrolled in a federal or state government plan, meaning Medicare, Medicaid, CHIP, TRICARE, or VA coverage disqualify you from the savings card
• Obtain the prescription from a participating pharmacy

Enrollment takes roughly five minutes online at the Praluent website or via the prescriber's office. The card is typically activated within one business day and can be applied to the first fill.

For uninsured Tennessee patients without government coverage disqualification, Regeneron/Sanofi also maintain a patient assistance program (PAP) through which qualifying low-income patients may receive Praluent at no cost. Income thresholds and documentation requirements are managed by the manufacturer directly. [9]

The Clinical Evidence for Alirocumab: Why Cost Even Matters

Praluent is not a lifestyle supplement. The ODYSSEY OUTCOMES trial, published in the New England Journal of Medicine in 2018 (N=18,924), demonstrated that alirocumab 75 mg to 150 mg every two weeks reduced the rate of major adverse cardiovascular events (MACE: coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, unstable angina requiring hospitalization) by 15% relative to placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) over a median follow-up of 2.8 years in patients with recent acute coronary syndrome on high-intensity statin therapy. [10]

All-cause mortality was also reduced in the pre-specified subgroup with baseline LDL-C of 100 mg/dL or higher (HR 0.71; 95% CI 0.56 to 0.90). Mean LDL-C fell from 87.5 mg/dL at baseline to 53.3 mg/dL at 48 months in the alirocumab group versus 101.4 mg/dL in placebo. The absolute risk reduction for MACE was 1.6 percentage points over the trial duration, translating to a number needed to treat of approximately 63 over 2.8 years. [10]

These are not abstract numbers for Tennessee's cardiovascular disease burden. Tennessee ranks among the top ten states nationally for age-adjusted cardiovascular mortality, according to CDC data. [11] Access to a drug with this magnitude of MACE reduction has direct public-health consequences in a state where that access is blocked by cost for many patients.

Alirocumab Dosing: What Tennessee Patients Should Know

The FDA-approved dosing schedule for alirocumab is a subcutaneous injection given once every two weeks. The starting dose is 75 mg per injection. If LDL-C response is insufficient at 8 to 12 weeks (goal <70 mg/dL for high-risk ASCVD, or 50% reduction for HeFH patients not at absolute target), the dose can be uptitrated to 150 mg every two weeks.

Both doses are available as pre-filled single-dose auto-injectors (pens) that patients self-administer at home. The device design allows injection into the abdomen, upper arm, or thigh. Injection-site reactions occur in approximately 7% of patients versus 5% in placebo across ODYSSEY trial data, making them generally mild and not a common reason for discontinuation. [1]

Storage requirements: Praluent must be refrigerated at 36 to 46 degrees Fahrenheit. Unopened pens may be kept at room temperature (up to 77 degrees Fahrenheit) for up to 30 days. Tennessee summers make room-temperature storage a practical concern during shipping; patients should inspect delivery packaging for evidence of temperature excursion. [1]

Maximally Tolerated Statin First: The Non-Negotiable Step

Alirocumab is not a first-line lipid-lowering agent. Every major guideline, every commercial insurer's prior authorization criteria, and every TennCare review requires documentation that the patient is on a maximally tolerated statin before PCSK9 inhibitor therapy begins. The ACC/AHA 2019 cholesterol guidelines place PCSK9 inhibitors in the third step of therapy after high-intensity statin plus ezetimibe. [8]

High-intensity statins include atorvastatin 40 to 80 mg daily and rosuvastatin 20 to 40 mg daily. "Maximally tolerated" applies when a patient has documented myopathy, myalgia with elevated CK, or other confirmed adverse effects preventing dose escalation. Statin intolerance claims without documentation will fail prior authorization review at every Tennessee commercial plan.

Ezetimibe 10 mg daily costs under $10 per month generic and should be added before PCSK9 inhibitor initiation in most patients. This step is frequently omitted and represents a common prior authorization failure point in Tennessee practice. [8]

What Happens If You Stop Praluent Abruptly?

LDL-C returns toward baseline within approximately four to eight weeks of stopping alirocumab. Alirocumab has a half-life of roughly 17 to 20 days, meaning two missed injections translate to near-complete washout. There is no withdrawal syndrome and no rebound above pre-treatment LDL-C levels. Patients who must pause therapy (cost gap, supply issue, surgery) can restart without a loading dose at the same 75 mg starting dose. [1]

Cost-driven gaps in therapy are common with branded PCSK9 inhibitors. This is precisely why the savings card program, compounding access, and prior authorization documentation are not administrative annoyances. They directly determine whether a high-risk Tennessee patient stays on a drug that the ODYSSEY OUTCOMES data shows saves lives.

Tennessee Prescribers: Documentation Checklist for Alirocumab PA

For clinicians in Tennessee submitting prior authorizations for alirocumab (commercial or TennCare T2D pathway), the following documentation package maximizes first-pass approval probability:

• Dated lipid panel showing LDL-C at or above goal threshold while on current statin
• Statin name, dose, and duration on current regimen (with ezetimibe added or intolerance documented)
• ICD-10 codes: Z82.49 (family history, ischemic heart disease) plus I25.10 (atherosclerotic heart disease) or E78.01 (pure hypercholesterolemia, familial)
• For HeFH: Dutch Lipid Clinic Network (DLCN) score of 6 or higher, or positive cascade genetic testing result
• Prescriber specialty (cardiology or endocrinology on file often reduces review time by 3 to 5 days)

The American College of Cardiology's 2023 PCSK9 Expert Consensus Decision Pathway notes: "Clinicians should anticipate and proactively address insurer barriers by submitting complete clinical documentation at the time of initial request, including the patient's 10-year ASCVD risk estimate and prior statin history." [12]